new article is published in J.Clinical Cancer Research 13, 7314-7321, December 15, 2007 by the team from MDACC:
Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part Sarcoma
http://clincancerres.aacrjournals.org/c ... 13/24/7314
Immunohistochemistry for jag-1, midkine, and angiogenin in 33 human ASPS samples confirmed these results. Comparison with other sarcomas indicates that the ASPS angiogenic signature is unique. The most upregulated genes were midkine, angiogenin, jag-1, HIF1a and TGF-beta.
Angiogenesis-Promoting Gene Patterns in ASPS
related article - Metabolic targeting of hypoxia and HIF1
Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy.
It is recognized that ASPS is a highly chemoresistant tumor.
An article from Stanford University School of Medicine suggest that pharmacologic targeting of the unique metabolism of solid tumors could alter the tumor microenvironment to provide more favorable conditions for anti-tumor therapy, it was recently found that HIF1 alfa is significantly overexpressed in ASPS tumors and may represent an attractive target.
This article is avail. with the full free text at:
http://www.pubmedcentral.nih.gov/articl ... d=17517659
and the abstract at:
Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy.
http://www.ncbi.nlm.nih.gov/pubmed/17517659
"we describe a strategy in which the mitochondrial metabolism of tumor cells is increased by pharmacologic inhibition of hypoxia-inducible factor 1 (HIF1) or its target gene pyruvate dehydrogenase kinase 1 (PDK1). This acute increase in oxygen consumption leads to a corresponding decrease in tumor oxygenation. Whereas decreased oxygenation could reduce the effectiveness of some traditional therapies, we show that it dramatically increases the effectiveness of a hypoxia-specific cytotoxin. This treatment strategy should provide a high degree of tumor specificity for increasing the effectiveness of hypoxic cytotoxins, as it depends on the activation of HIF1 and the presence of hypoxia, conditions that are present only in the tumor, and not the normal tissue."
It is recognized that ASPS is a highly chemoresistant tumor.
An article from Stanford University School of Medicine suggest that pharmacologic targeting of the unique metabolism of solid tumors could alter the tumor microenvironment to provide more favorable conditions for anti-tumor therapy, it was recently found that HIF1 alfa is significantly overexpressed in ASPS tumors and may represent an attractive target.
This article is avail. with the full free text at:
http://www.pubmedcentral.nih.gov/articl ... d=17517659
and the abstract at:
Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy.
http://www.ncbi.nlm.nih.gov/pubmed/17517659
"we describe a strategy in which the mitochondrial metabolism of tumor cells is increased by pharmacologic inhibition of hypoxia-inducible factor 1 (HIF1) or its target gene pyruvate dehydrogenase kinase 1 (PDK1). This acute increase in oxygen consumption leads to a corresponding decrease in tumor oxygenation. Whereas decreased oxygenation could reduce the effectiveness of some traditional therapies, we show that it dramatically increases the effectiveness of a hypoxia-specific cytotoxin. This treatment strategy should provide a high degree of tumor specificity for increasing the effectiveness of hypoxic cytotoxins, as it depends on the activation of HIF1 and the presence of hypoxia, conditions that are present only in the tumor, and not the normal tissue."